Cannabis Vaporization Temperatures: Boiling Points, Aerosol Kinetics & COA Matrix (Doctor’s Guide)
Medical Review & Authorship: Written and clinically reviewed by Benjamin Caplan, MD, Board-Certified Family Physician, Chief Medical Officer at CĒD Clinic, and author of The Doctor-Approved Cannabis Handbook. Browse all articles and clinical research by Dr. Caplan →
Last updated: October 2026. Grounded in peer-reviewed pharmacokinetic, thermodynamic, and clinical trial literature.
If you search for a “cannabis vaporization temperature chart” online, you will find hundreds of identical, beautifully designed infographics across dispensary websites and cannabis lifestyle blogs. Almost every single one of them recites the exact same tidy figures: CBG activates at 126°F, THC boils at 315°F, CBD boils at 338°F, and CBN is a proven sedative for sleep.
I have a confession to make as a physician: For years, I handed those exact same charts to thousands of my own patients at CĒD Clinic.
Like many healthcare providers and medical educators navigating the early days of cannabinoid medicine, I wanted clean, accessible answers for patients struggling with chronic pain, insomnia, and anxiety. The charts looked scientific. They gave patients a sense of neat, dials-and-switches control: “Set your device to 315°F for daytime focus, or dial up to 338°F for anti-inflammatory relief.”
It was only after digging deeply into physical chemistry, thermodynamic aerosol kinetics, and the newest randomized clinical trials that the reality became undeniable: Almost none of that conventional advice is supported by modern science.
Cannabis is medicine. But when commercial marketing lore masquerades as clinical dogma, patients waste money, inhale unintended combustion byproducts, or fail to achieve symptom relief. This guide is the clinical antidote-built to ground dry-flower and concentrate vaporization in actual aerosol physics, laboratory extraction studies, and human clinical trials.
Contents of This Clinical Guide
- The Master Visual Infographics (Dry-Flower & COA Matrix)
- The “Single-Degree Boiling Point” Myth: Why Vaporizers Aren’t Light Switches
- The 5 Thermodynamic Temperature Bands: What the Studies Measure
- The 3-Tier Evidence Hierarchy: Debunking Dispensary Folklore
- Why Temperature Is Not Dose: The 55%-83% Extraction Gap
- How to Decode Your Product’s Certificate of Analysis (COA)
- Download the Print-Ready 4-Page Master PDF (Free)
- Complete Peer-Reviewed Bibliography & Trial Citations
1. Master Visual Infographics: The 2026 Clinical Reference
To help patients visualize how thermal energy alters the aerosol they inhale, CĒD Clinic synthesized the laboratory data into two complementary visual tools. These charts replace static “boiling points” with continuous dynamic release ranges.

The companion tool below allows patients to bridge the gap between dispensary lab testing and real-world inhalation:

2. The “Single-Degree Boiling Point” Myth: Why Vaporizers Aren’t Light Switches
The foundational flaw of virtually every cannabis chart on the web is the assumption that cannabinoids possess simple, universally agreed-upon boiling points that behave like water boiling at 212°F.
In physical chemistry, that model falls apart for three critical reasons:
A. Published Cannabinoid Boiling Points Disagree by Hundreds of Degrees
Unlike simple molecules like ethanol or water, heavy phytocannabinoids decompose thermally when heated to their theoretical normal boiling points at atmospheric pressure. As a result, scientists must estimate boiling points using vacuum distillations, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), or vapor pressure equations.
Recent physical chemistry literature (such as Beuning et al. in the Journal of Breath Research 2026, and Turovsky et al. in the Journal of Cannabis Research 2025) demonstrates that published laboratory estimates for $\Delta^9$-THC’s normal boiling point disagree by over 300°F-ranging from approximately 473°F (245°C) in older literature up to 797°F (425°C) in rigorous thermodynamic modeling. Presenting a single exact degree (like “315°F”) as a physical constant is scientifically indefensible.
B. Vaporization Is a Dynamic Rate Process, Not an On/Off Switch
A compound does not wait for its boiling point to transition from liquid to gas. Molecules exert vapor pressure at all temperatures. Evaporation is a continuous function of temperature, surface area, and convective airflow. As heat increases, the rate of evaporation accelerates exponentially (physics calculations show THC evaporation velocity triples roughly every 36°F increase). Cannabinoids begin entering the vapor stream at temperatures far below their normal boiling points.
C. The 20-to-40 Second Terpene Flash-Off
Laboratory aerosol measurements (Eyal et al., Cannabis and Cannabinoid Research 2023) reveal a critical temporal reality that static temperature charts omit entirely: At 356°F (180°C), the vast majority of delicate monoterpenes (like myrcene, pinene, and limonene) and even heavier sesquiterpenes (like $\beta$-caryophyllene) evaporate within the first 20 to 40 seconds of heating.
During that initial 20-40 second window, only about 10% to 20% of the THC has left the plant material. If a patient continues inhaling from the same chamber 3, 5, or 8 minutes later, they are inhaling almost exclusively cannabinoids from which the aromatic terpenes have already been stripped.
3. The 5 Thermodynamic Temperature Bands: What the Studies Show
Instead of arbitrary single-degree markers, clinical science evaluates vaporization across 5 distinct thermal zones:
| Temperature Setting | What the Studies Show (Laboratory & Clinical Data) | What the Patient Notices |
|---|---|---|
|
338° to 356°F (170° to 180°C) Light Zone |
MEASURED At 356°F, most monoterpenes and sesquiterpenes evaporate within 20-40 seconds, prior to substantial THC release (~10% at 20s, ~20% at 40s). THCA-to-THC decarboxylation approaches completion in ~40 seconds. MEASURED A landmark laboratory study (Pomahacova et al., 2009) identified its poorest cannabinoid-to-byproduct ratio at 338°F, as lower thermal energy fails to liberate full cannabinoid payloads while still evaporating volatile plant oils. |
REASONED Exceptional terpene flavor profile; light, clear-headed, uplifting functional effect; slower onset of intoxication. Ideal for daytime work and microdosing. |
|
356° to 392°F (180° to 200°C) Balanced Zone |
REASONED Kinetic equations calculate that THC evaporation velocity accelerates roughly 3x for each 36°F increase. REASONED Bridges lighter aromatic release with accelerating cannabinoid yield; reliable decarboxylation with minimal throat irritation. |
REASONED Robust balance of aroma and pronounced psychoactivity. Moderate physical relaxation without severe motor heaviness. Excellent for social settings, mood modulation, and mild chronic pain. |
|
392° to 428°F (200° to 220°C) Strong Zone |
MEASURED The most extensively researched medical band. At 410°F (210°C), clinical evaluations (Lanz et al., 2016) demonstrated release of 55% to 83% of total available THC and 46% to 70% of CBD, depending on chamber physics. Electric models achieved ≥97% THCA-to-THC and ≥95% CBDA-to-CBD decarboxylation. MEASURED At 428°F, ~34% of THC evaporates by 20s and ~50% by 40s; THCA decarboxylation is virtually instantaneous (<20s). |
REASONED Dense, visible vapor clouds. Flavor transitions from pine/citrus notes to toasty, roasted herbal notes. Substantial body sedation and potent analgesia. The primary clinical band for severe neuropathic pain and insomnia. |
|
428° to 446°F (220° to 230°C) Max Studied |
MEASURED Pomahacova et al. documented their highest total THC extraction yield and most favorable cannabinoid-to-byproduct ratio at 446°F (230°C). REASONED Operating near this ceiling risks thermal degradation of THC into secondary oxidation artifacts (such as CBN). |
REASONED Maximum physical intensity. Hot vapor can induce coughing and airway irritation. Terpene flavors are depleted. Recommended only for high-tolerance patients requiring total extraction. |
|
Above 446°F (> 230°C) Past Studied |
UNPROVEN Zero controlled clinical data supports daily vaporization above 446°F. Thermal breakdown studies (Meehan-Atrash et al., 2021) confirm that excessive power and heat produce reactive volatile organic compounds (VOCs) such as benzene, methacrolein, and polycyclic aromatic hydrocarbons. Some devices begin scorching cellulose, turning vaporization into low-temperature combustion. |
UNPROVEN Harsh, acrid, burnt taste. Significant respiratory irritation. Not a sensible or health-conscious setting. |
4. The 3-Tier Evidence Hierarchy: Debunking Dispensary Folklore
Every claim on the CĒD Clinic matrix is held to an epistemological grading system. When we subject popular cannabis assertions to clinical scrutiny, several widely accepted dispensary beliefs fail to hold up:
Myth 1: “CBN is a proven sedative for insomnia.” → UNPROVEN
Dispensaries market cannabinol (CBN) as “cannabis Ambien.” However, in a rigorous randomized, double-blind, placebo-controlled crossover trial published in the Journal of Sleep Research (Lavender et al., 2026), oral CBN failed to improve primary objective sleep metrics. Comprehensive systematic reviews (da Silva et al., Sleep Medicine Reviews 2025; Lavender et al., Current Psychiatry Reports 2024) conclude that the popular claims surrounding CBN do not match the clinical evidence.
Myth 2: “Inhaling $\alpha$-pinene prevents THC memory deficits.” → UNPROVEN IN HUMANS
It is frequently asserted that the pine-scented terpene $\alpha$-pinene inhibits acetylcholinesterase, shielding the brain from THC-induced memory fog. While animal models demonstrate anti-inflammatory activity, a controlled human trial in healthy adults (Kumar et al., Medical Cannabis and Cannabinoids 2025) demonstrated that vaporized $\alpha$-pinene had no effect alone and failed to reduce THC memory impairment.
Myth 3: “Myrcene causes couch-lock sedation.” → UNPROVEN IN HUMANS
Dispensary budtenders routinely point to myrcene levels to predict whether a strain is “indica” or “sativa.” Yet in clinical pharmacology, there is no controlled human trial showing myrcene induces sedation. Preclinical mouse models conflict directly: early work showed muscle relaxation at massive doses, while recent trials (Alayoubi et al., Pain 2025) showed pain modulation without changes in locomotor movement.
Validated Synergy: Limonene + THC → REASONED / MEASURED IN PILOT
In an elegant 2024 double-blind trial conducted at Johns Hopkins (Spindle et al., Drug and Alcohol Dependence), researchers co-administered vaporized D-limonene alongside $\Delta^9$-THC. Limonene selectively mitigated THC-induced anxiety and paranoia ratings in healthy adults. When inhaled completely alone, limonene produced zero subjective effect. This represents true, measured pharmacology for the “entourage effect.”
5. Why Temperature Is Not Dose: The 55%-83% Extraction Gap
One of the most frequent clinical errors patients make is assuming that setting their device to 410°F guarantees an identical pharmacological dose every time.
In a landmark university trial led by Christoph Lanz and Rudolf Brenneisen (PLoS One, 2016), researchers bench-tested commercial dry-flower vaporizers operated under standardized laboratory puffing protocols at 410°F (210°C). The recovery yield of released THC varied from 55% to 83% solely based on device engineering.
Thermal Transfer Mechanics
Convection devices (drawing hot air through unheated flower) extract compounds differently than conduction devices (heating chamber walls). Convection preserves volatile terpenes longer, whereas conduction continuously cooks flower between draws.
Puff Dynamics & Airflow
Rapid, sharp inhalations draw excessive cool room air into the chamber, dropping thermal extraction temperatures by 20°F-40°F mid-draw. Slow, sustained, gentle draws allow the heating element to maintain equilibrium.
Clinical Takeaway: Temperature provides direction, not dosage. Chamber pack density, grind coarseness, inhalation duration, and battery voltage stability all modulate real-world delivery.
6. How to Decode Your Product’s Certificate of Analysis (COA)
To use the CĒD Clinic COA Matrix effectively, follow this 3-step clinical workflow whenever purchasing dry flower or full-spectrum concentrates:
- Check the Product Label: Locate the independent laboratory analysis (often accessible via a QR code). Identify the dominant monoterpenes ($\alpha$-pinene, myrcene, limonene), sesquiterpenes ($\beta$-caryophyllene, humulene), and cannabinoid acids (THCA, CBDA).
- Choose Your Primary Goal:
- For Daytime Anxiety Relief & Focus: If your flower tests high in limonene or pinene, keep your vaporizer strictly between 338°F and 356°F. Take 1-2 initial draws to capture the delicate aromatics without excessive THC sedation.
- For Daytime Functional Pain Relief: Target the 356°F to 392°F band to activate moderate THC and CBD conversion while preserving secondary terpenes.
- For Severe Chronic Pain & Sleep Induction: If your product is rich in caryophyllene and high THCA, step up to the 392°F to 428°F band for maximum cannabinoid decarboxylation and systemic absorption.
- Step Up Incrementally: Start near 356°F (180°C). Only increase your temperature in 10°F-20°F steps if symptom relief is insufficient. Stop before 446°F to avoid combustion toxins.
7. Download the Complete Master PDF Guide (Free)
CĒD Clinic Vaporizer Temperature Guide (PDF)
Download the full, high-resolution 4-page reference document designed for patients and medical practitioners. Includes the high-res Dry-Flower Guide, the COA Matching Matrix, the complete laboratory aerosol kinetics breakdown, and all 20+ peer-reviewed citations through 2026.
8. Peer-Reviewed Bibliography & Clinical Foundations
Aerosol Kinetics, Thermodynamics & Byproducts
- Eyal AM, Berneman Zeitouni D, Tal D, et al. Vapor pressure, vaping, and corrections to misconceptions related to medical cannabis’ active pharmaceutical ingredients’ physical properties and compositions. Cannabis Cannabinoid Res. 2023;8(3):414-425. doi:10.1089/can.2021.0173. PMID 35442765.
- Lanz C, Mattsson J, Soydaner U, Brenneisen R. Medicinal cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis. PLoS One. 2016;11(1):e0147286. doi:10.1371/journal.pone.0147286. PMID 26784441.
- Pomahacova B, Van der Kooy F, Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa. Inhal Toxicol. 2009;21(13):1108-1112. doi:10.3109/08958370902748559. PMID 19852551.
- Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci. 2006;95(6):1308-1317. doi:10.1002/jps.20574. PMID 16637053.
- Beuning CN, Berry JL, Paulechka E, et al. Vapor pressure measurements on Δ9-tetrahydrocannabinol, cannabidiol, and cannabinol to inform cannabis breathalyzer development. J Breath Res. 2026;20(1). doi:10.1088/1752-7163/ae3794. PMID 41529405.
- Turovsky EH, Moriarty K, et al. Application of thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) to estimate the normal boiling points of THCV and THC. J Cannabis Res. 2025;8(1):9. doi:10.1186/s42238-025-00373-w. PMID 41366713.
- Meehan-Atrash J, Luo W, McWhirter KJ, et al. The influence of terpenes on the release of volatile organic compounds and active ingredients to cannabis vaping aerosols. RSC Adv. 2021;11(19):11714-11723. doi:10.1039/d1ra00934f. PMID 35423635.
Clinical Cannabinoid Evidence
- Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022;20(1):259. doi:10.1186/s12916-022-02459-1. PMID 35982439.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358. PMID 26103030.
- Solmi M, De Toffol M, Kim JY, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382:e072348. doi:10.1136/bmj-2022-072348. PMID 37648266.
- Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011-2020. doi:10.1056/NEJMoa1611618. PMID 28538134.
- Lavender IG, Marshall NS, et al. Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial. J Sleep Res. 2026;35(4):e70284. doi:10.1111/jsr.70284. PMID 41698831.
- Lavender I, Garden G, et al. Using cannabis and CBD to sleep: an updated review. Curr Psychiatry Rep. 2024;26(12):712-727. doi:10.1007/s11920-024-01564-7. PMID 39612156.
- da Silva GHS, Barbosa EC, et al. Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia: a systematic review and meta-analysis. Sleep Med Rev. 2025;84:102156. doi:10.1016/j.smrv.2025.102156. PMID 40929927.
- Cuttler C, Stueber A, et al. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind field trial. Sci Rep. 2024;14(1):16163. doi:10.1038/s41598-024-66879-0. PMID 39003387.
Terpenoids & Phytochemical Trials
- Spindle TR, Zamarripa CA, Russo E, et al. Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults. Drug Alcohol Depend. 2024;257:111267. doi:10.1016/j.drugalcdep.2024.111267. PMID 38498958.
- Kumar L, Spindle TR, Zamarripa CA, et al. The individual and interactive effects of alpha-pinene and delta-9-tetrahydrocannabinol in healthy adults. Med Cannabis Cannabinoids. 2025;8(1):144-157. doi:10.1159/000547014. PMID 40734690.
- Gertsch J, Leonti M, Raduner S, et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A. 2008;105(26):9099-9104. doi:10.1073/pnas.0803601105. PMID 18574142.
- You J, Shin YK, Seol GH. Alleviating effect of lavender and its major components on postherpetic pain: a randomized controlled trial. BMC Complement Med Ther. 2024;24(1):54. doi:10.1186/s12906-024-04362-z. PMID 38267936.
- Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. doi:10.1111/j.1476-5381.2011.01238.x. PMID 21749363.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
